How Psychiatric NPs Get More Weight Loss/GLP-1 Patients

You’ve probably noticed it in your inbox, your social feeds, maybe even in conversations with colleagues: everyone’s talking about Ozempic, Wegovy, and the wave of GLP-1 medications reshaping how we think about weight loss. As a psychiatrist or psychiatric nurse practitioner, you might be wondering if this is just noise—or if there’s a real opportunity here for your practice.

Here’s the short answer: Yes, there’s an opportunity. And it’s bigger than most providers realize.

The longer answer involves understanding patient demand, the unique role psychiatric providers can play, what it actually takes to start offering weight-loss services, and whether the economics make sense. Let’s break it down.

Why Psychiatric Providers Are Uniquely Positioned for Weight Loss Treatment

The Mind-Body Connection Isn’t Optional

Here’s something that gets lost in all the Ozempic hype: weight and mental health are deeply interconnected. Research consistently shows that patients with obesity have higher rates of depression, anxiety, and eating disorders. Many of your current patients struggle with weight gain from psychiatric medications—antipsychotics, mood stabilizers, even some antidepressants can pack on 20, 30, 40+ pounds.

GLP-1 medications (semaglutide, tirzepatide) aren’t just diabetes drugs repurposed for weight loss. They work on brain pathways that regulate appetite, reward, and food-seeking behavior. Early evidence suggests these medications may actually improve quality of life and mood in patients with obesity, without increasing depression or suicidal ideation—concerns that have plagued older weight-loss medications.

As one psychiatrist putting this into practice writes: ‘These systems are inseparable. Treating metabolic illness can improve mental health, and vice versa. For psychiatrists already managing medication-induced weight gain, integrating GLP-1s isn’t a departure from psychiatric care—it’s an evolution of it.’

You Already Have the Skills

Think about what weight-loss treatment actually requires:

• Medication management and monitoring
• Addressing behavioral change and motivation
• Managing side effects and patient expectations
• Understanding comorbid conditions
• Long-term patient relationships

Sound familiar? That’s because it’s what you do every day in psychiatric care.

Unlike a random telehealth startup staffing up with newly graduated NPs who’ve never prescribed anything, you bring years of medication management experience. You understand adherence challenges. You know how to have hard conversations about lifestyle change. You’re already comfortable with the fact that medications aren’t magic—they’re tools that work best alongside behavioral support.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Market Reality: Massive Demand, Growing Competition

Patient Demand Is Real and Growing

Let’s look at the numbers:

• By late 2024, approximately 18 million Americans (about 7% of adults) were using GLP-1 medications for weight loss
• Surveys show another 30-35% of Americans express interest in trying these medications
• The telehealth weight-loss market hit $6.9 billion in 2023, growing at 8%+ annually
• In every U.S. state, adult obesity prevalence exceeds 25%—in Texas and Pennsylvania, it’s over 35%

That’s not a fad. That’s a fundamental shift in how people approach weight management.

Search behavior tells the story: queries like ‘how to get Ozempic for weight loss’ generated over 100,000 monthly searches in 2024. Patients aren’t waiting for their primary care doctor to bring it up—they’re actively hunting for providers who can prescribe these medications.

Competition Is Intense but Differentiation Is Possible

Here’s the reality check: you’re not the only one who noticed this opportunity. National telehealth companies (Ro, Hims, Henry Meds, Sequence/WeightWatchers) have poured millions into capturing this market. Novo Nordisk itself partnered with telehealth platforms to offer subsidized GLP-1 prescriptions. Google Ads for weight-loss keywords are expensive—some companies spent over $7 million bidding on Ozempic-related search terms.

But here’s what most of these companies don’t have: integrated mental health expertise.

They’re volume plays. Quick video appointments, minimal follow-up, cookie-cutter protocols. Many patients report feeling like they’re on an assembly line—get your prescription, see you in three months (maybe).

This is where you can differentiate:

• You can screen for and treat co-occurring depression, anxiety, and eating disorders
• You can address medication-induced weight gain for patients already in psychiatric treatment
• You can provide the behavioral support that makes the difference between a patient dropping out at month three versus staying the course
• You can offer actual continuity of care instead of rotating providers

Position yourself as the weight-loss provider who treats the whole person, not just the number on the scale.

State-by-State Considerations: Where Can You Practice?

Your ability to expand into weight-loss services depends significantly on where you’re licensed and what your credential is.

Scope of Practice Realities

States with Full NP Practice Authority (for experienced NPs):

• California: As of January 2026, NPs with ≥3 years experience can practice independently in all settings. This means psychiatric NPs can open weight-loss practices without physician oversight.
• New York: NPs with >3,600 hours (roughly 2 years) of supervised practice can work independently. Gives PMHNPs flexibility to add weight management services.
• Illinois: APRNs can obtain full practice authority after 4,000 hours of experience plus additional training. Growing number of independent NP practices in the state.

States Requiring Physician Collaboration:

• Texas: NPs must have a supervising physician agreement. If you’re an NP wanting to start a weight-loss practice, you’ll need an MD/DO partner (which adds overhead but is manageable).
• Pennsylvania: Still requires collaborative agreements for NPs, though legislation for full practice authority keeps getting introduced.
• Florida: Complicated—FNPs and other primary care NPs can qualify for autonomous practice, but psychiatric NPs still need physician collaboration.

Bottom line: If you’re a psychiatrist (MD/DO), scope isn’t an issue anywhere. If you’re a PMHNP, know your state’s rules and factor in collaboration costs if required.

Telehealth and Licensing

Every state on this list allows telehealth for weight-loss consultations, which is good news. But you need to be licensed in each state where your patients are located.

Notable exceptions:

• Florida allows out-of-state providers to register for a telehealth-only license (easier than getting a full Florida license) if you’re already licensed elsewhere. This can expand your reach.
• California and Texas require full state licensure—no shortcuts. However, both states are large markets worth the investment.

The Interstate Medical Licensure Compact (IMLC) can streamline multi-state licensing for physicians—New York and Pennsylvania are members, making it easier to practice across state lines. California and Texas are not in the compact, so you’ll go through regular application processes there.

Insurance Coverage: The Wild Card

Here’s something most providers don’t realize: state Medicaid coverage of GLP-1 weight-loss medications varies dramatically, and it impacts your patient economics.

States with Broad Medicaid Coverage (covering Wegovy, Zepbound for obesity):

• California: Medi-Cal covers obesity medications; spent $1.4 billion on GLP-1s in 2024. If you’re in California and take Medi-Cal, you have access to a huge patient population.
• Pennsylvania: PA Medicaid covers these medications; spent nearly $300 million in 2024. Strong state support for obesity treatment.

States with No or Limited Medicaid Coverage:

• New York, Illinois, Florida: State Medicaid does NOT cover GLP-1s for obesity (only for diabetes). Most patients will be commercial insurance or cash-pay.
• Texas: Partial coverage—some plans cover Wegovy but restrictions are common.

Why does this matter? Because patient retention is directly tied to medication affordability. If your state’s Medicaid covers the meds, you can build a sustainable practice serving lower-income patients. If not, you’ll need to focus on commercially insured or cash-paying patients—which is fine, but narrows your market.

Medicare still generally doesn’t cover weight-loss medications, though the Trump administration announced pilot programs in early 2026 that may change this by 2027.

The Economics: What Does Patient Acquisition Actually Cost?

Let’s talk numbers, because this is where a lot of providers get burned.

The Myth of Cheap Patient Acquisition

You’ll see claims that digital marketing can bring patients for ‘$30-50 per lead.’ That’s fantasy for psychiatric and weight-loss services.

Here’s the reality:

DIY Marketing (SEO, Google Ads, Directories):

• Google Ads for weight-loss keywords: $15-40+ per click, with typical conversion rates of 2-5%. That’s $300-800+ per booked appointment after factoring in clicks that don’t convert.
• SEO takes 6-12 months of consistent investment before meaningful patient flow—content creation, technical optimization, backlinks. Figure $2,000-4,000/month in agency fees or your own time.
• Psychology Today, Zocdoc, and similar directories: $35-100+ per booking on top of monthly subscription fees ($200-400/month). You’re competing with hundreds of providers on the same platform.
• Hidden costs: staff time qualifying leads, no-show rates from cold inquiries, failed campaigns that need testing, A/B testing landing pages.

All-in patient acquisition cost through DIY marketing: $200-500+ when you factor in everything—and that’s after months of building momentum.

Platform vs. DIY: The ROI Equation

Here’s where a platform like Klarity Health’s model makes economic sense:

Platform Model (Pay-Per-Appointment):

• No upfront marketing spend or monthly subscriptions
• You pay a standard fee only when a qualified patient books and shows up
• Patients are pre-screened and matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—scale up or down as needed

The Math:

• If you’re spending $3,000-5,000/month on marketing with uncertain results and 3-6 month lag time…
• Versus paying per booked appointment with patients ready to start immediately…
• The platform model removes risk entirely—guaranteed ROI instead of gambling on marketing channels

This doesn’t mean DIY marketing is wrong. If you have the budget, patience, and expertise (or can hire someone who does), building your own patient acquisition engine can be more cost-effective long-term. But for most psychiatrists and NPs—especially those starting out or trying to scale quickly—the platform model is the smarter business decision.

Revenue Potential

What can you actually make from weight-loss services?

Average Patient Lifetime Value:

• Initial consultation: $150-250 (typically not covered by insurance, so cash or superbill)
• Monthly follow-ups: $100-150 per visit
• Average treatment duration: 8-12 months (though about 50% of patients discontinue by one year due to cost or reaching goals)
• Patient LTV: $1,000-1,500 over the course of treatment

If your acquisition cost is $200-300 (via platform or efficient marketing), that’s a 3:1 to 5:1 ROI—solid for any medical practice.

Medication margins are typically minimal (patients get prescriptions filled at regular pharmacies), so your revenue comes from service fees. Some practices partner with compounding pharmacies offering lower-cost semaglutide, which may offer revenue-sharing arrangements—but ensure you’re compliant with state anti-kickback laws.

What It Actually Takes to Start

1. Clinical Competence

You don’t need a fellowship in obesity medicine, but you do need to:

• Understand GLP-1 pharmacology: mechanism of action, dosing protocols, drug interactions
• Know how to screen for contraindications (personal/family history of medullary thyroid cancer, pancreatitis history, etc.)
• Manage common side effects (nausea, constipation, etc.)
• Provide basic lifestyle counseling or partner with a dietitian/health coach
• Monitor for complications and know when to refer (e.g., gallbladder issues)

Resources: Obesity Medicine Association offers certification courses; many CME providers have GLP-1-specific training. Budget a weekend to get up to speed.

2. Operational Setup

• EHR/Documentation: Add weight-loss templates to your existing system. Track weight, vital signs, medication titration, side effects.
• Informed Consent: Create clear consent forms addressing off-label use (if applicable), expected results, costs, and potential risks.
• Pharmacy Relationships: Identify which pharmacies in your area stock these medications (or have reliable access). Many patients hit insurance rejections—having a backup plan (manufacturer savings programs, compounding alternatives) is essential.
• Lab Monitoring: Baseline labs (lipid panel, HbA1c if applicable, liver function) and periodic follow-up.

3. Marketing and Positioning

Don’t just add ‘weight loss’ to your website and hope patients find you. Be strategic:

• SEO: Write content answering questions patients are Googling: ‘Can a psychiatrist prescribe Ozempic for weight loss?’ ‘Managing weight gain from antidepressants,’ ‘GLP-1 medications and mental health.’
• Niche Down: Position yourself for a specific patient type—’Weight loss for patients on psychiatric medications,’ ‘Integrated mental health and metabolic care,’ ‘Weight management for women in midlife.’
• Social Proof: With appropriate consents, share patient success stories (weight lost, mood improvements, medication adjustments). Before/after data, testimonials—people want to see results.
• Local Outreach: Partner with therapists, primary care docs, endocrinologists who might refer patients with comorbid psychiatric issues.

4. Compliance and Ethics

Weight-loss marketing is heavily scrutinized. Avoid:

• Guaranteeing specific weight loss amounts
• Using misleading before/after photos
• Making exaggerated safety claims
• Anything that looks like a ‘quick fix’ scam

Emphasize evidence-based care, realistic expectations, and your qualifications. The FDA monitors prescription drug advertising; state medical boards watch for deceptive practices. Stay on the right side of these lines.

Controlled Substance Prescribing: Know the Federal Rules

If you’re considering adding appetite suppressants like phentermine (Adipex-P) alongside or instead of GLP-1s, know this:

The DEA’s temporary telemedicine flexibilities expire December 31, 2025. After that, federal law requires at least one in-person visit before prescribing controlled substances (Schedule II-V) via telehealth to new patients. Phentermine is Schedule IV, so it falls under this rule.

What this means:

• You can prescribe GLP-1 medications (semaglutide, tirzepatide) entirely via telehealth—they’re not controlled substances.
• If you want to prescribe phentermine, you’ll need to either see the patient in person initially or coordinate with a local provider for that visit.
• Stimulants (Schedule II, sometimes used off-label for binge eating) face even stricter restrictions in some states (e.g., Florida bans telehealth prescribing of Schedule II except narrow exceptions).

Most providers focusing on weight loss are moving away from controlled appetite suppressants anyway, given the effectiveness and better side-effect profile of GLP-1s. But if you incorporate them, factor in the in-person visit requirement.

Real Talk: Should You Actually Do This?

This Is a Good Fit If:

• You’re looking to diversify revenue beyond traditional therapy/med management
• You’re comfortable with a more consumer-facing, outcome-driven service (weight loss attracts patients who expect visible results)
• You want to serve patients holistically—addressing the mental health and metabolic issues that so often overlap
• You’re willing to invest time in learning the clinical and business aspects of weight management
• You can handle the fact that some patients will be transient (they hit their goal and leave) rather than long-term therapy clients

This Might Not Be For You If:

• You prefer the slower, relationship-focused pace of psychotherapy
• You’re uncomfortable with the commercialization of medicine (weight loss leans more ‘wellness business’ than traditional psychiatry)
• You don’t want to deal with insurance denials, prior authorizations, and helping patients navigate medication costs
• You’re in a state where scope-of-practice restrictions make it operationally difficult (e.g., NP in Texas with no physician partner lined up)

The Hybrid Model Works Best

Many psychiatrists aren’t going ‘all in’ on weight loss—they’re adding it as a service for existing patients who struggle with medication-induced weight gain, then expanding as word spreads. This lets you test the waters without overhauling your entire practice.

Start with patients you already see for depression or bipolar disorder who’ve gained weight on meds. Offer GLP-1s as part of their psychiatric care. Refine your protocols, get comfortable with dosing and follow-up, then consider marketing more broadly.

The Bottom Line

Should psychiatrists start a weight-loss practice? If ‘start’ means building something thoughtful, evidence-based, and differentiated from the telehealth mills flooding the market—then yes, absolutely.

The demand is there. The clinical fit is real. The economics can work if you’re smart about patient acquisition and retention.

But go in with your eyes open. This isn’t a passive income stream. It’s a real service that requires clinical competence, operational systems, and ongoing patient support. Do it well, and you’re offering something genuinely valuable: integrated care that addresses both mental and metabolic health in a way most providers ignore.

Ready to explore adding weight-loss services without the upfront marketing risk? Klarity Health’s platform connects psychiatrists and psychiatric NPs with pre-qualified patients seeking GLP-1 weight management and mental health support. You control your schedule, see patients via telehealth, and only pay when patients book—no monthly fees, no ad spend gambles. Learn more about joining Klarity’s provider network.

FAQ: Psychiatrists and Weight-Loss Practice

Can psychiatrists legally prescribe GLP-1 medications for weight loss?

Yes. Psychiatrists (MD/DO) can prescribe any FDA-approved medication within their scope of practice, including GLP-1s like Wegovy (approved for obesity) and Ozempic (approved for diabetes, often used off-label for weight loss). As long as you’re practicing within standard of care—proper evaluation, informed consent, monitoring—it’s legal. Psychiatric NPs can also prescribe these medications in states where they have prescriptive authority (most states, though some require physician collaboration).

Do I need special certification to offer weight-loss services?

No specific certification is legally required. However, taking CME courses in obesity medicine or GLP-1 pharmacology is highly recommended to ensure you’re providing evidence-based care. The Obesity Medicine Association offers certificates and training that can boost your credibility with patients and reduce liability risk.

How do GLP-1 medications affect mental health?

Current research suggests GLP-1 agonists are safe from a psychiatric standpoint and may even improve mood and quality of life in patients with obesity. They do NOT increase depression or suicidal ideation—a concern with older weight-loss drugs. Some patients report reduced food obsessions and better emotional regulation. That said, monitor for any mood changes, especially in patients with pre-existing psychiatric conditions, and adjust psychiatric medications as weight changes (some psych med levels can be affected by significant weight loss).

What’s the typical patient journey in a weight-loss practice?

Initial consultation (30-45 min): History, assess candidacy, discuss goals and expectations, order baseline labs. Start medication at low dose (semaglutide 0.25 mg weekly or tirzepatide 2.5 mg weekly). Monthly follow-ups (15-20 min): Titrate dose, manage side effects, provide behavioral support, track progress. Most patients stay on treatment 6-12 months; some continue long-term for weight maintenance. About half discontinue within a year (due to cost, reaching goal, or intolerance).

How much should I charge for weight-loss consultations?

Initial visits typically run $150-250 (cash-pay or superbill for out-of-network reimbursement). Follow-ups are $100-150. Most insurers don’t cover weight-loss consultations separately (though they may cover the medications themselves), so expect to operate largely as a cash/self-pay service or superbill patients. Price competitively for your market—check what local concierge practices and telehealth companies charge.

What if my state Medicaid doesn’t cover GLP-1s for obesity?

Focus your marketing on commercially insured or self-pay patients. Many patients are willing to pay out-of-pocket for medications if they work (typical cost is $900-1,300/month without insurance, but manufacturer savings cards can reduce this to $500-600). You can also help patients access compounded semaglutide (currently $200-400/month through compounding pharmacies) as a bridge until insurance coverage expands. Monitor state policy—Medicaid coverage is expanding, and CMS may add Medicare coverage in 2027.

How do I handle patients who want GLP-1s but don’t meet clinical criteria?

Set clear eligibility criteria based on FDA labeling and clinical guidelines: BMI ≥30, or BMI ≥27 with weight-related comorbidity (hypertension, diabetes, sleep apnea, etc.). If a patient with BMI 24 wants it for vanity weight loss, explain it’s off-label, the safety profile is established primarily in higher BMI populations, and insurance won’t cover it. You can decline or, if the patient insists on paying cash and you’re comfortable, prescribe off-label with informed consent acknowledging this. Most providers stick to evidence-based criteria to avoid patient complications and maintain credibility.

What are the biggest operational mistakes providers make starting weight-loss services?

1. Underestimating patient acquisition costs (thinking you’ll just ‘get patients easily’)
2. Not having a system for insurance prior authorizations and pharmacy issues—this eats staff time
3. Poor patient communication around expectations (patients think they’ll lose 50 lbs in 2 months; reality is 10-15% body weight over 6-12 months)
4. No follow-up or retention strategy—patients ghost after a few months when side effects hit or they plateau, and you don’t have a process to re-engage them
5. Ignoring compliance/legal requirements (proper informed consents, avoiding misleading marketing, DEA rules if prescribing controlled substances)

Avoid these by setting up robust systems before you launch.

Sources and References

1. Dr. Alex Spencer (Metabolic Psychiatrist) – Should Psychiatrists Prescribe GLP-1s? Available at: drlewis.com/glp-1-medications-psychiatry (Published: January 4, 2026) [High reliability – Authored by MD, evidence-cited]

2. Bask Health – Persona Marketing for GLP-1 Weight Loss Available at: bask.health/blog/glp-1-weight-loss-persona-marketing (Published: January 2, 2026) [Medium reliability – Marketing data, recent survey statistics]

3. Kaiser Family Foundation (KFF) – Medicaid Coverage of and Spending on New Drugs Used for Weight Loss Available at: kff.org/policy-watch/medicaid-coverage-of-and-spending-on-new-drugs-used-for-weight-loss (Published: January 16, 2026) [High reliability – Nonpartisan health policy research]

4. MagMutual – Telemedicine Prescriptions and the Ryan Haight Act: What You Need to Know Available at: magmutual.com/healthcare-insights/article/telemedicine-prescriptions-and-the-ryan-haight-act (Updated: November 29, 2024) [High reliability – Accurate summary of DEA rules]

5. Real Chemistry – State-by-State Analysis of Medicaid Coverage for GLP-1 Weight Loss Available at: realchemistry.com/state-by-state-analysis-of-medicaid-coverage-for-glp-1-weight-loss (Updated: January 2, 2025) [Medium reliability – Detailed claims data, business perspective]

6. Marketdata LLC – $6.9 Billion Weight Loss Telehealth Market Grows But Gets Crowded Available at: blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded (Published: April 16, 2024) [Medium-High reliability – Industry market research]

7. STAT News – Telehealth and Pharma GLP-1 Partnerships Increase Drug Access, Boost Sales Available at: statnews.com/2025/11/18/telehealth-pharma-glp1-partnerships-increase-drug-access-boost-sales (Published: November 18, 2025) [High reliability – Investigative health journalism]

8. Klein A, et al. – Trends in Paid Advertising for Glucagon-Like Peptide-1 Receptor Agonists on a Consumer-Directed Online Platform JAMA Network Open. Available at: pmc.ncbi.nlm.nih.gov/articles/PMC12579337 (Published: October 31, 2025) [High reliability – Peer-reviewed study]

9. Centers for Disease Control and Prevention – Adult Obesity Prevalence Maps Available at: cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html (Updated: 2024) [High reliability – Official government statistics]

10. California Health Care Foundation – New California Rules Allow Nurse Practitioners to Practice Without Physician Supervision Available at: chcf.org/resource/new-rules-allow-nurse-practitioners-practice-without-physician-supervision (Updated: April 22, 2025) [High reliability – Reliable regulatory summary]

11. Florida Board of Medicine – Telehealth FAQs Available at: flhealthsource.gov/telehealth/faqs (Updated: 2023) [High reliability – Official state policy guidance]

12. Florida Senate – CS/HB 607 — Advanced Registered Nurse Practitioners Available at: flsenate.gov/Committees/BillSummaries/2020/html/607 (Published: March 2020) [High reliability – Statutory primary source]

13. Robard Corporation – Top 7 Weight Loss Clinic Marketing Mistakes Available at: robard.com/blog/weight-loss-clinic-marketing-mistakes (Published: 2023) [Medium reliability – Practitioner consultant advice with marketing statistics]

14. Robard Corporation – How to Measure Marketing ROI in Your Weight Loss Practice Available at: robard.com/blog/how-to-measure-marketing-roi-in-your-weight-loss-practice (Published: 2022) [Medium reliability – General best practices]

15. Willis Towers Watson – GLP-1 Drugs in 2025: Cost, Access and the Future of Obesity Treatment Available at: wtwco.com/en-us/insights/2025/04/glp-1-drugs-in-2025-cost-access-and-the-future-of-obesity-treatment (Published: 2025) [Medium-High reliability – Employer benefits analysis]

Source:

• https://bask.health/blog/glp-1-weight-loss-persona-marketing#:~:text=movement%20that%20changes%20healthcare
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=consumers%20like%20the%20convenience
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=I%20want%20to%20address%20a,1%20receptor%20agonist%20medications
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=%2A%20GLP,1s%20as%20part%20of%20integrated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=neurotransmitter%20function%20,psychiatric%20care
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=Traditionally%2C%20psychiatrists%20prescribe%20psychiatric%20medications,primarily%20indicated%20for%20metabolic%20conditions
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=Top%20Things%20to%20Know%20About,Weight%20Loss%20Telehealth%20Services
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=Major%20Players%3A%20Digital%20health%20companies,and%20independent%20provider%20practices
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=,independent%20provider%20practices
• https://www.statnews.com/2025/11/18/telehealth-pharma-glp1-partnerships-increase-drug-access-boost-sales/#:~:text=Patients%20searching%20for%20those%20deals,that%20partner%20with%20Novo%20Nordisk